Article: Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/ HCV coinfected patients (abstract) - August 2015 - NJM
Issue: 2015 > August > original article

Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/ HCV coinfected patients



ORIGINAL ARTICLE
J.E. Arends, J.T.M. van der Meer, D. Posthouwer, W. Kortmann, K. Brinkman, S. van Assen, C. Smit, M. van der Valk, M. van der Ende, J. Schinkel, P. Reiss, C. Richter, A.I.M. Hoepelman
AbstractFull textPDF

Abstract

Background: Recent publications have reported superior efficacy of telaprevir- or boceprevir-based triple therapy over conventional peginterferon-alfa/ribavirin therapy, albeit with varying rates of adverse events and treatment discontinuations in HIV/ HCV coinfected patients. Therefore, the aim of this study is to describe the effectiveness of triple therapy in an HIV/HCV coinfection cohort in the Netherlands.
Methods: HIV-infected patients with chronic HCV genotype 1 starting triple therapy including either boceprevir or telaprevir were enrolled, 26% had F3-F4 fibrosis. Data were assessed at Week 4, 8, 12, 24, 48 and SVR12 (i.e. absence of detectable plasma HCV RNA 12 weeks after completion of treatment). Failure was defined as discontinuation of treatment due to virological failure, adverse events or loss to follow-up.
Results: A total of 53 HIV/ HCV coinfected patients started peginterferon-alfa/ribavirin therapy with either boceprevir (n = 29) or telaprevir (n = 24). SVR12 was achieved in 19 (66%) of the boceprevir-treated and 15 (63%) of the telaprevir-treated patients. Both prior relapse and achievement of a rapid virological response were associated with a higher SVR12 rate. Non- response, breakthrough and relapse occurred in 4, 1 and 5 patients on boceprevir and 3, 2, 2 on telaprevir, respectively. One patient was lost to follow-up and one patient died due to progression of liver failure. Except for these two patients, no treatment discontinuations were observed due to adverse events.
Conclusion: In HIV/ HCV coinfected patients, boceprevir or telaprevir triple therapy was well tolerated and resulted in favourable SVR12 rates comparable with previous publications concerning HCV mono-infected patients.